ライフサイエンスコーパス: remission

1 predict conversion to psychosis and/or CHR-P remission.

2 ed to detect subclinical iTTP in patients in remission.

3 ds are effective in bringing active EoE into remission.

4 published definitions of spontaneous asthma remission.

5 e, during which PET is mainly used to assess remission.

6 gnant clones in vivo, and inducing molecular remission.

7 a role in the mechanism by which EEN induces remission.

8 ctive treatments that could promise lifelong remission.

9 on should clearly define all 3 components of remission.

10 hich needed to be extended due to inadequate remission.

11 ations and their stabilization after disease remission.

12 in patients who achieved a complete clinical remission.

13 infected cells could lead to treatment-free remission.

14 ed per patient-week before achieving partial remission.

15 erapy that would not diminish the chances of remission.

16 therapeutic intervention to achieve lifelong remission.

17 urrence of psychotic depression or sustained remission.

18 nts in the primary efficacy analysis were in remission.

19 t not with body mass index or local surgical remission.

20 in 10/14 patients (71.4%) achieving complete remission.

21 s are effective for long-term maintenance of remission.

22 nd all patients ultimately achieved complete remission.

23 c immunity, and is associated with prolonged remission.

24 leukemia (AML) patients who entered complete remission.

25 sychosis over 2 to 3 years and 30% achieving remission.

26 n the host TET2 gene was associated with CLL remission.

27 herapy regimens and frequent HSCT upon first remission.

28 ad cancer progression and only 1 patient had remission.

29 auville scores 1-3 define complete metabolic remission.

30 of the patients, and 7.6% reached functional remission.

31 ceived Hu19-CD828Z T cells obtained complete remission.

32 and other protocols aimed at achieving HIV-1 remission.

33 of response but higher fractions of durable remissions.

34 elected patients has shown a lack of durable remissions.

35 A majority of patients had sustained remissions.

36 Following remission, 1,017 patients were randomly assigned to a th

37 mponents necessary to define the presence of remission: (1) absence of glucose-lowering therapy (GLT)

38 3.6% (EU5); remission = 48.0 and 53.0%; deep remission = 11.9 and 13.3%.

39 acute infections, during active disease and remission; (2) the prevalence of acute infections in a c

40 ctedly high cumulative incidence of death in remission (22% at 5 years).

41 of them had relapse (median follow-up after remission = 3.6 years).

42 active disease = 40.1% (US) and 33.6% (EU5); remission = 48.0 and 53.0%; deep remission = 11.9 and 13

43 At last follow-up, 55.3% were in disease remission, 5.0% had stable disease, 28.1% were deceased,

44 9, 2.11-7.18), active cancer (progressing vs remission: 5.20, 2.77-9.77), and receipt of azithromycin

45 I=-4.63, -1.09) and achieved higher rates of remission (56.7% compared with 30%; number needed to tre

46 Poorer overall remission (57% versus 96%, P = 0.004), 2-year (46% versu

47 d the percentage of patients having clinical remission according to a DAS28-CRP of less than 2.6.

48 M] = 0.87 [US] and 0.78 [EU5]) compared with remission (AdjM = 0.92 and 0.91) and deep remission (Adj

49 th remission (AdjM = 0.92 and 0.91) and deep remission (AdjM = 0.93 and 0.91) (all P < 0.05 compared

50 rovides the longest follow-up of patients in remission after anti-CD19 CAR T-cell therapy.

51 tal of 19 Stage IIIC-IV OC patients in first remission after conventional therapy.

52 LT3-ITD-positive AML in complete hematologic remission after HCT were randomly assigned to receive fo

53 Five patients experienced drug-free remission after rituximab therapy and none of them had r

54 hundred two patients with HR-NB who achieved remission after salvage therapies were enrolled in this

55 Lack of diabetes remission after surgically-induced weight loss may be as

56 0 participants with type 2 diabetes in their remission analysis, which examined an outcome of type 2

57 Of 17 HSCT survivors, 7 are in complete remission and 5 are in good partial remission without tr

58 iated with non-inferior results for clinical remission and adverse events (AE).

59 nd statistically non-inferior) incidences of remission and AE to a course of 6 weeks.

60 tained stool metagenomes from CD patients in remission and assessed gut microbiome composition before

61 The differences between remission and cure in RA are first defined, followed by

62 h 20 (51%) of 39 patients achieving complete remission and five (13%) achieving complete remission wi

63 lack of universally accepted definitions of remission and other disease states, such as low disease

64 re behavioral changes as complex as clinical remission and relapse within hours and days of treatment

65 iomarkers of response that are predictive of remission and survival.

66 eek to increase response rates, the depth of remission and the durability of benefit.

67 he proportion of patients achieving complete remission and those with a complete remission with incom

68 iations with time from biopsy to proteinuria remission and time to a composite progression outcome (>

69 erapy was well-tolerated and induced durable remissions and transfusion independence in patients with

70 on, (3) patient/provider agreement regarding remission, and (4) no use of systemic corticosteroids.

71 with lymphoma and 3 with CLL) had a complete remission, and 1 had remission of the Richter's transfor

72 tment-related death (from septicemia) during remission, and 1 secondary myeloid leukemia.

73 f antihypertensive medications, hypertension remission, and BP control according to current guideline

74 f histo-endoscopic mucosal healing, clinical remission, and corticosteroid-free remission at week 44

75 ents, eight with active disease and seven in remission, and nine healthy individuals.

76 ion, incidence rate of disease relapse after remission, and risk factors for disease relapse.

77 Exploratory endpoints, including clinical remission, are reported in the article, although the stu

78 cell transplantation (HCT) in first complete remission as a time-dependent variable revealed treatmen

79 , there is an opportunity to consider asthma remission as a treatment goal.

80 ork is a first step toward developing asthma remission as a treatment target and should be refined th

81 xpert consensus on core components of asthma remission as a treatment target.

82 activity of Treg are higher in the clinical remission as compared to the active RA (p value < 0.0001

83 nalysis demonstrates that escitalopram-based remission associates to functions related to cellular pr

84 ely; 61.5% and 77.8% of patients remained in remission at 1 year.

85 27 [95% CI 0.12 to 0.64], P=0.003) and renal remission at 6 months (IRR 0.40 [95% CI 0.18 to 0.90], P

86 line in the DAS28-CRP and the achievement of remission at week 12 but was associated with more seriou

87 clinical remission at week 16 and endoscopic remission at week 12 or 16 using the multiple comparison

88 The primary endpoints were clinical remission at week 16 and endoscopic remission at week 12

89 clinical remission, and corticosteroid-free remission at week 44 (all P < .05) in patients who recei

90 Remission based on DRSP score was attained by 20 women i

91 ed to develop a test to identify patients in remission, based on endoscopic analysis, and monitor CD

92 first or consecutive complete haematological remission (blast counts <5% in bone marrow) or myelodysp

93 ally, five studies reported data on clinical remission but clinical and methodological heterogeneity

94 differences between treatments in depression remission, but additional benefits in cognition at 12-mo

95 ve chemotherapy depletes AML cells to induce remission, but is infrequently curative.

96 hronic lymphocytic leukaemia, achieving deep remissions by potently inducing apoptosis and increasing

97 ignificant differences were observed between remission categories.

98 The primary outcomes were clinical remission (clinical) and bowel mucosal damage (preclinic

99 ng BOT 1.0 mg twice daily were in persistent remission compared with 4.4% of patients in the placebo

100 Clinical remission comprised 12 or more months with (1) absence o

101 l tissue macrophages (STM), which persist in remission, contribute to joint homeostasis.

102 cell immunotherapy has resulted in complete remission (CR) and durable response in highly refractory

103 ssed time to first chart-documented clinical remission (CR) and symptom resolution (UC: rectal bleedi

104 einduction, 15 of 16 not reaching a complete remission (CR) before transplantation, 9 of 10 treated w

105 id leukemia (AML) include achieving complete remission (CR) by clinicopathological criteria followed

106 The primary end point was complete remission (CR) on induction.

107 lapse (CIR) in patients achieving a complete remission (CR) or CR with incomplete hematologic recover

108 Complete remission (CR) plus CR with partial hematologic recovery

109 3, none of these parameters reduced complete remission (CR) rate and ORR with VenG.

110 High complete remission (CR) rates often include minimal residual dise

111 The overall response rate (complete remission [CR]/CR with incomplete count recovery) was 72

112 Nineteen of 21 participants (90.5%) met remission criteria (defined as a score <11 on the Montgo

113 analysis, 19 of 22 participants (86.4%) met remission criteria.

114 patients with active disease vs patients in remission (defined as a simple endoscopic score for CD o

115 Remission definitions were extracted and categorised by

116 ied other chronic inflammatory diseases with remission definitions.

117 The pooled complete remission did not significantly differ with anti-CD19 CA

118 fitness to tolerate intensive chemotherapy, remission duration, and presence of a targetable mutatio

119 We analyzed influence of TDT on remission, early death, and overall survival (OS) in uni

120 ividuals with HIV to experience therapy-free remission, even though deeper tissue reservoirs were not

121 hether posterior hippocampal volumes predict remission following antidepressant treatment.

122 The London patient has been in HIV-1 remission for 30 months with no detectable replication-c

123 l modelling suggests that the probability of remission for life (cure) is 98% in the context of 80% d

124 et cells and greater than 99% probability of remission for life with 90% donor chimerism.

125 enetoclax is highly active at achieving deep remission for most treated patients with CLL, including

126 diagnosis, the patient had been in complete remission for nine years.

127 tion was associated with higher incidence of remission (for age >=40 years vs. <40 years: aHR, 1.29;

128 course was not significantly associated with remission (for the ITT population, hazard ratio 1.1, 95%

129 Phase 3 evaluated a remission framework created using consensus findings.

130 Ideally, pregnancy should be planned during remission from bipolar disorder and lithium prescribed w

131 d with pyramidal cell disinhibition and with remission from MDD.

132 Ten (14%) of 69 patients died in complete remission from sepsis (two [3%]), cardiac arrest (one [1

133 , and a capacity to discriminate patients in remission from those with mild or moderate to severe act

134 r adults with EoE in clinical and histologic remission, from 29 European study sites, were randomly a

135 All patients who achieved partial remission had a normal baseline LDH.

136 Individuals with LBP, including those in remission, had similar overall motor abundance, but use

137 Remission has been identified as a top priority by peopl

138 mide was associated with a greater chance of remission (hazard ratio [HR] = 3.84, P < .0001) and a lo

139 hose patients treated with rituximab who had remission; however, follow-up duration in those patients

140 ative cells and efficiently induces complete remission; however, many patients relapse and die of the

141 ted the trial per protocol, either achieving remission (i.e., 24-item Hamilton Rating Scale for Depre

142 HLA allele (switch therapy) can also induce remissions if initial EBV-CTLs are ineffective.

143 in 50% (n = 18), additional rituximab led to remission in 25% (n = 9), and the remaining 25% were tre

144 resulted in clinical and histologic disease remission in 3 patients and marked improvement in the ot

145 igh-dose intravenous immunoglobulin achieved remission in 50% (n = 18), additional rituximab led to r

146 RIS alone resulted in remission in 50% of LTx patients but none of the SBTx pa

147 which examined an outcome of type 2 diabetes remission in adults >=18 years and which had been publis

148 g) engraftment within the islets and induced remission in all mice.

149 eralized framework for clinical and complete remission in asthma, on and off treatment, developed on

150 and link these events to the maintenance of remission in CD.

151 animal studies, and improvements in clinical remission in IBD patients.

152 of immune system renewal and durable disease remission in MS.

153 more effective than placebo for induction of remission in patients with active mild to moderate UC.

154 key characteristic associated with long-term remission in patients with hematologic malignancies.

155 medications for induction and maintenance of remission in patients with or without prior exposure to

156 exclusive enteral nutrition (EEN) can induce remission in patients with pediatric Crohn's disease (CD

157 induce long-term or even permanent drug-free remission in people with multiple sclerosis (MS).

158 Immune-regulatory mechanisms of drug-free remission in rheumatoid arthritis (RA) are unknown.

159 stained aviremia, are unlikely to induce HIV remission in the absence of additional interventions.

160 , there is great interest in achieving viral remission in the absence of antiretroviral therapy.

161 Chemotherapy induces remission in the majority of patients, but relapse rates

162 topic NB and it caused long-term (6+ months) remissions in 80% to 100% of NB and sarcoma xenografts.

163 KTE-X19 induced durable remissions in a majority of patients with relapsed or re

164 t landscape for oncology, leading to durable remissions in a subset of patients, but also a broad ran

165 Estimation of remission incidence and identification of associated pre

166 eline clinical factors predictive of reduced remission incidence included longer duration of uveitis

167 The cumulative medication-free, person-year remission incidence within 5 years was 32.7% (95% confid

168 rthropathy were also associated with reduced remission incidence.

169 eated patients (71.8%) experienced drug-free remission (incidence rate = 0.28/person-year [PY], 95% c

170 utcome measures were the incidence of ocular remission, incidence rate of disease relapse after remis

171 arms (17/44 vs. 16/49; p=0.51), as were the remission incidences in the per-protocol (PP) population

172 rom toxicity or treatment abandonment during remission induction.

173 RTX was comparable to CYC in remission-induction (BVAS/WG=0) at 6 months (IRR 1.37 [9

174 Addition of PLEX showed no benefit on remission-induction at 6 months (IRR 0.73 [95% CI 0.44 t

175 ients received CYC (n=161) or RTX (n=64) for remission-induction, and 51 were also treated with PLEX.

176 Fixed-duration therapy with a treatment-free remission is a particularly appealing prospect, since it

177 Molecular remission is a primary goal of treatment.

178 A second remission is achieved after one cycle of lymphodepletion

179 diagnosis of AHA remains high until partial remission is achieved, and weekly measured FVIII activit

180 Remission is commonly used as an outcome in research stu

181 effects of FGF1 and that sustained diabetes remission is dependent on intact melanocortin signaling.

182 efore reaching full biochemical efficacy and remission is not achieved in many patients.

183 = 2.53, 95% CI = 1.24 to 5.15, p = 0.01) and remission (k = 3, OR = 1.84, 95% CI = 1.32 to 2.57, p <

184 ; however, most patients do not have disease remission lasting >18 months.

185 ly been during the twenty-first century that remission, let alone cure, has been a regularly achievab

186 icantly (P < .0001) associated with clinical remission, lower mean disease activity scores, and great

187 Complete remission, partial remission, marrow complete remission, or haematological

188 Depressed patients, even after remission, might also benefit from less commonly used tr

189 ree of endoscopic inflammatory activity into remission, mild activity, and moderate to severe activit

190 reatment level necessary to achieve clinical remission: mild, moderate and severe.

191 ical end points included safety and clinical remission (modified Mayo score <=2; endoscopic subscores

192 with disease relapse (n = 8) and patients in remission (n = 13).

193 ll as treatment outcomes, including complete remission, no response, relapse, early death, and treatm

194 In the intention-to-treat (ITT) population, remission occurred in 37 (84%) of the patients in the 3-

195 le standard therapies can lead to an initial remission of aggressive cancers, they are often only a t

196 sible tablet (BOT) vs placebo in maintaining remission of EoE.

197 aily) was superior to placebo in maintaining remission of EoE.

198 t models of type 2 diabetes (T2D), sustained remission of hyperglycemia can be induced by a single in

199 After the remission of MDD, the olfactory dysfunction was improved

200 The primary endpoint was the remission of MS at 12 months.

201 gh-dose corticosteroids induced the complete remission of neurological symptoms in 4 of 5 patients.

202 eatment with mGluR2 PAM resulted in complete remission of panic symptoms.

203 Nineteen patients with schizophrenia during remission of psychotic symptoms and 19 age- and sex-comp

204 to ameliorate, cure, and sustain the durable remission of the disease.

205 ith CLL) had a complete remission, and 1 had remission of the Richter's transformation component but

206 cates interpretation of previous research on remission of type 2 diabetes and the implications for pe

207 es; however, a widely accepted definition of remission of type 2 diabetes is lacking.

208 Remission of type 2 diabetes occurred in 66.7% (4/6) aft

209 Complete remissions of a variety of B-cell malignancies lasting >

210 Remissions of up to 9 years are ongoing.

211 commended phase 2 dose who achieved complete remission or complete remission with incomplete haematol

212 with a transplant performed not in complete remission or from a cord-blood unit, a relapse after tra

213 ts at 12 months may be the result of natural remission or of radiotherapy, but the changes are of mar

214 as a single agent, MI-3454 induced complete remission or regression of leukemia in mouse models of M

215 features among those destined for adolescent remission or the correction of early childhood anomalies

216 proportion of patients who achieved complete remission or who had cytokine release syndrome or neurot

217 ission without a Mayo endoscopic score = 0 ("remission"), or active disease.

218 emission, partial remission, marrow complete remission, or haematological improvement were included i

219 With egg and peanut OIT, a limited remission, or sustained unresponsiveness (SU), has furth

220 ients achieve complete responses and disease remission, others are completely resistant to the therap

221 composite response, complete haematological remission, overall clinicohaematological response, overa

222 Complete remission, partial remission, marrow complete remission,

223 These trajectory groups and remission patterns were replicated in an independent sam

224 removal of infiltrated leukocytes during the remission phase was markedly accelerated in CMH-treated

225 t diagnosis, 4-21 years at HSCT, in complete remission pre-HSCT, and with an HLA-compatible related o

226 or IDH2 mutations, with prolonged molecular remissions prevalent for NPM1 mutations.

227 The addition of ATRA resulted in a higher remission rate (21.9% with ATRA v 13.5% without ATRA; od

228 -frequency (100 Hz) MST produced the highest remission rate (33.3%).

229 r stable disease >=6 months/partial/complete remission rate (52.1% versus 30.4% P < 0.001) (all multi

230 Clinical remission rate (achieving grade 0 hepatic steatosis) in

231 DD achieved a remission rate (RR) of 64% and a very good hematologic r

232 n of ATRA to decitabine resulted in a higher remission rate and a clinically meaningful survival exte

233 n therapy remains to be determined, the high remission rate in de novo AML warrants additional invest

234 -controlled trials are needed to confirm the remission rate observed in this initial study.

235 The complete remission rate was 70%.

236 e of the high risk of rejection and the poor remission rate with the use of checkpoint inhibitors in

237 stration, we found higher response (41%) and remission rates (29%) following rapamycin + ketamine com

238 R = 1.08, 95% CI (0.76, 1.52), p = 0.67) and remission rates (HR = 0.89, 95% CI (0.57, 1.39), p = 0.6

239 le secondary outcomes were rates of response/remission rates and dropout/discontinuation due to adver

240 kin lymphoma in part on the basis of durable remission rates of approximately 40% in a clinical trial

241 ansplantation at the time of second complete remission remains the only reliable option with curative

242 sion with a Mayo endoscopic score = 0 ("deep remission"), remission without a Mayo endoscopic score =

243 A partial-remission response (defined as an insulin dose-adjusted

244 n peripheral monocytes and T cells from iMCD remission samples compared with healthy controls.

245 nal consensus is reached, studies describing remission should clearly define all 3 components of remi

246 Any new consensus definition of remission should include unambiguous glycaemic threshold

247 02) and in patients with active CD versus in remission state (PSQI 75.8% vs. 33.3%, p < 0.01; ESS: 45

248 reased TNFAIP3 levels at relapse compared to remission state in MOG-AAD patients.

249 ratio of inhibitory activity for indicating remission status are 92.31% (95% CI 63.97-99.81) and 11.

250 e Ht volumes were positively associated with remission status at weeks 8 and 16.

251 clinical characteristics (recurrent status, remission status, antidepressant medication use, age of

252 than controls at baseline and also following remission, suggesting a trait-like connectomic character

253 ated with a greater likelihood of depression remission, suggesting that this ERP measure can predict

254 ve response, defined as complete and partial remission, tested at a one-sided significance level of a

255 patients that will remain in treatment-free remission (TFR).

256 ient and society, of achieving some level of remission to restore generic and disease-related HRQoL a

257 (high) and MerTK(pos)LYVE1(pos)) with unique remission transcriptomic signatures enriched in negative

258 on underwent CNS assessments across four ATI remission trials.

259 risk-score for predicting treatment-induced remission using naive T-cells had an odds ratio of 15.4

260 rate (RR) of 64% and a very good hematologic remission (VGHR) rate of 48% after 3 months.

261 V-EoE was more likely to attain histologic remission via dietary restriction (P < .0001).

262 The percentage of patients having remission was 30.0% with upadacitinib and 13.3% with aba

263 ility of maintaining complete haematological remission was 55% (95% CI 32-73) and the probability of

264 Composite remission was 64% (two-stage 95% CI 48-79), with 20 (51%

265 er 88 months, and estimated 5-year sustained remission was 77%.

266 The pooled complete remission was 80% (95% CI 75.5-84.8) and heterogeneity b

267 Remission was achieved after 12 weeks of treatment.

268 Endoscopic remission was achieved by 10% (P < .1 vs placebo), 8%, 8

269 mong the 220 patients in the study, clinical remission was achieved by 13% of patients receiving 3 mg

270 A low proportion of MerTK(pos) STMs in remission was associated with increased risk of disease

271 Maintenance of remission was defined as absence of clinical and histolo

272 For the primary analysis, remission was defined as inactive uveitis while off trea

273 nge, 24 to 82) who were enrolled, a complete remission was observed in 98%.

274 A report on defining remission was published (but not formally endorsed) in D

275 Clinical remission was reached by 16% of the patients, which is i

276 Clinical remission was reached by 16.4% of the patients, and 7.6%

277 did not express CCR5 (CCR5Delta32/Delta32); remission was reported at 18 months after analytical tre

278 The use of medication and remission was verified.

279 High response rates and durable remissions were typically associated with NPM1 or IDH2 m

280 ad the highest rates of complete proteinuria remission, whereas patients in clusters with extensive l

281 n after lymphodepleting chemotherapy induces remission which is consolidated with four more CAR T-cel

282 ance can result in clinical and histological remission, while food reintroduction can cause recurrenc

283 tients into one of the following categories: remission with a Mayo endoscopic score = 0 ("deep remiss

284 The EHI identified patients in remission with a significantly higher AUROC value than t

285 TS13 is primarily closed in iTTP patients in remission with ADAMTS13 activity >50% and undetectable a

286 during acute iTTP, as well as in patients in remission with ADAMTS13 activity <50% and in half of the

287 The EHI identified patients in remission with an AUROC of 0.962 in validation cohort 1

288 s and for monitoring disease progression and remission with distinct therapeutic approaches.

289 One complete remission with incomplete count recovery was observed in

290 who achieved complete remission or complete remission with incomplete haematological recovery.

291 complete remission and those with a complete remission with incomplete neutrophil or platelet count r

292 remission and five (13%) achieving complete remission with incomplete neutrophil or platelet count r

293 ff value of 20 points identified patients in remission with the highest level of sensitivity (97.1% i

294 ff value of 50 points identified patients in remission with the highest level of specificity (100% in

295 ys; INP pretreatment resulted in longer-term remissions with 40% of mice surviving 150 days and 30% s

296 alivary gland uptake translated into partial remission, with an odds ratio (OR) of 60.265 (95% confid

297 ted LDH implied a reduced chance for partial remission, with an OR of 0.094 (95% CI, 0.017-0.518), bu

298 ayo endoscopic score = 0 ("deep remission"), remission without a Mayo endoscopic score = 0 ("remissio

299 complete remission and 5 are in good partial remission without treatment (together, 12 of 17 [70.6%])

300 ixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy.